Impact of selective digestive decontamination on respiratory tract *Candida* among patients with suspected ventilator associated pneumonia. A meta-analysis.

James C Hurley, D Med Sci, M Epi, PhD, FRACP

Author affiliations;

- Associate Professor, Department of Rural Health, Melbourne Medical School, University of Melbourne,
- Physician and Head of General Medicine, Ballarat Health Services,
- and Chairman, Infection Control Committees, St John of God Hospital and Ballarat Health Services, Ballarat, Victoria, Australia.

Corresponding author address:

Internal Medicine Service

Ballarat Health Services,

PO Box 577,

Ballarat, Australia, 3353

Telephone (61.3) 53204322 Fax (61.3) 53.204472

e-mail jamesh@bhs.org.au; hurleyjc@unimelb.edu.au

Running head: Respiratory tract *Candida* and SDD.

Word count: 4144 (not including abstract 247)

Tables, 2; Figures 5

Compliance with Ethical Standards – see lines 456-468

Abstract:

Purpose: to establish the incidence of respiratory tract colonization with *Candida* (RT *Candida*) among ICU patients receiving mechanical ventilation within studies in the literature. Also of interest is its relationship with candidemia and the relative importance of topical antibiotic (TA) use as within studies of selective digestive decontamination (SDD) versus other candidate risk factors towards it.

Methods: The incidence of RT *Candida* was extracted from component (control and intervention) groups decanted from studies of various TA and non-TA ICU infection prevention methods and summary estimates derived using random effects. A benchmark RT *Candida* incidence to provide overarching calibration was derived using (observational) groups from studies without any prevention method under study. A multi-level regression model of group level data was undertaken using generalized estimating equation (GEE) methods.

Results: RT *Candida* data were sourced from 113 studies. The benchmark RT *Candida* incidence is 1.3; 0.9 -1.8% (mean and 95% confidence intervals). Membership of a concurrent control group of a study of SDD ($p=0.02$), the group wide presence of candidemia risk factors ($p<0.001$) and proportion of trauma admissions ($p=0.004$) but neither the year of study publication, nor membership of any other component group, nor the mode of respiratory sampling are predictive of the RT *Candida* incidence. RT *Candida* and candidemia incidences are correlated.

Conclusions: RT *Candida* incidence can serve as a basis for benchmarking. Several relationships have been identified. The increased incidence among concurrent control groups of SDD studies cannot be appreciated in any single study examined in isolation.

49 **Key words:** Intensive care unit; Topical antibiotic; Selective Digestive Decontamination;
50 Ventilator associated pneumonia; *Candida*.
51

Introduction

Respiratory tract colonization with *Candida* (RT *Candida*) among patients with suspected ventilator associated pneumonia (VAP) has been reported in numerous studies [1-113]. Both the overall incidence and the clinical significance for the individual patient are uncertain. True *Candida* pneumonia in this patient group is thought to be rare [114, 115]. Among a tally of 2490 isolates from 24 studies, fungi (species unspecified) accounted for only 0.9% of pathogenic isolates [116]. While current guidelines [114, 115] do not recommend treatment of RT *Candida*, it remains of interest for at least four reasons.

Firstly, colonization with *Candida* is believed to be a key intermediary step towards invasive candidiasis although the role of RT *Candida* in this respect is unclear. The respiratory tract, being a site not normally colonized by *Candida*, may provide a unique insight into factors influencing the incidence of *Candida* colonization. Thirdly, RT *Candida* may be a risk factor for specific bacterial infections due to molecular interactions [117, 118].

Finally, the influence topical antibiotic (TA) use as a method to prevent ICU acquired bacterial colonization and infection, as within studies of selective digestive decontamination (SDD) and selective oro-pharyngeal decontamination (SOD) [119, 120], on the incidence of *Candida* colonization is of longstanding interest. This question was raised in the first study of SDD [74, 142]. There appear to be subtle contextual effects of using topical antibiotics in the ICU on the incidence of candidemia [121], as with bacteremia [122] and also as with Ventilator Associated Pneumonia [123], which are

evident only through benchmarking the control group rates of these studies and which are not seen in studies of non-TA methods of ICU infection prevention.

RT *Candida* data is available from numerous studies of a broad range of VAP prevention methods [119, 120, 124-135]. Among this evidence base are those with concurrent versus non-concurrent study designs together with other study designs including those without any intervention. This heterogeneous evidence base provides a natural experiment [136, 137] with which to address some of these questions at the group level using methods as used in the analysis of cluster randomized trials.

Materials and methods,

Study selection and decant of groups

The literature search and analytic approach used here is as described previously [121].

These seven steps (Fig. 1; numbered arrows) are as follows;

1. An electronic search of PubMed, The Cochrane database and Google Scholar for systematic reviews containing potentially eligible studies was undertaken using the following search terms; “ventilator associated pneumonia”, “mechanical ventilation”, “intensive care unit”, each combined with either “meta-analysis” or “systematic review” up to December 2013.
2. Systematic reviews of studies of patient populations requiring prolonged (> 24 hours) ICU admission were then streamed into one of three categories; systematic reviews containing studies in which there was no intervention, studies with SDD as the intervention, or studies with an intervention other than SDD, for the prevention of VAP. For the purpose of this study, SDD is defined here as the use of protocolized topical antibiotic prophylaxis applied by the gastric or oro-pharyngeal route in the intervention group with or without the additional use of a parenteral antibiotic or any anti-fungal agent.
3. The studies were screened against the following eligibility criteria. Inclusion criteria; incidence data for ventilator associated pneumonia extractable as an incidence proportion being expressed as a proportion of numbers of patients among patients with an ICU stay of at least 24 hours. Exclusion criteria; studies limited to patients with the acute respiratory distress syndrome. Studies in a language other than English were included when the required data had been abstracted in an English language systematic review.

4. A hand search was undertaken for additional studies not identified within systematic reviews but otherwise meeting the eligibility criteria.
5. All eligible studies were then collated and any duplicate studies were removed.
6. Groups of patients receiving mechanical ventilation from studies without a VAP prevention method under study were labelled as observational groups. The studies of intervention studies were classified as follows. The non-TA based methods of VAP prevention used interventions other than topical antibiotics. These were usually delivered at either the gastric, airway or oral sites. The SDD studies were further sub-classified as to whether the control group was concurrent and co-located within the same ICU as the intervention group (concurrent control) or not (non-concurrent).
7. The component (control and intervention) groups were decanted from each study as follows;
 - The control and intervention groups from non-TA based methods were classified as indicated in the original study
 - Among studies of SDD, all groups that received prophylaxis with any regimen of topical antibiotic, whether or not an anti-fungal was included in the regimen, were designated as an SDD intervention group and all other groups from SDD studies were classified as a control group.

Data extraction

The RT *Candida* is the number of patients with *Candida* isolates from respiratory sampling per 100 patients with prolonged (>24 hours) stay in the ICU whether or not VAP has been documented. In addition, the following were also extracted where available; the overall incidence proportion of VAP, the incidence of candidemia, the incidence of *Candida* colonization at non-respiratory tract sites without regard to how this had been defined in each study and the proportion of admissions for trauma. Each of these were expressed as a

proportion using the number of patients with prolonged (>24 hours) stay in the ICU as the denominator. Other parameters extracted were whether the mode of diagnosis of VAP required bronchoscopic sampling and whether topical placebo had been used to achieve observer blinding.

Caterpillar plots

To generate caterpillar plots, the RT *Candida* data were logit transformed for analysis as previously [137]; with the total number of patients as the denominator (D), the number of patients with RT *Candida* as the numerator (N), and R being the RT *Candida* proportion (N/D), the logit(RT *Candida*) is $\log(N/(D-N))$ and its variance is $1/(D \cdot R \cdot (1-R))$. Note that for any group with a zero event rate (N=0), the addition of the continuity correction (i.e. $N+0.5$) is required to avoid indeterminate transformations of mean and variance. Using these pre-calculated logits and logit variances, group specific 95% confidence intervals, summary logits and the associated summary 95% CIs were generated using the 'metan' command in STATA. On the logit scale the 95% confidence intervals for a proportion are symmetrical and remain within the interval of 0 to 100%.

For each category of component group the summary mean logit RT *Candida* and associated 95% confidence interval were calculated using random effects methods. These were then back-transformed to the percentage scale. The benchmark is the summary mean RT *Candida* per 100 patients derived from the observational studies and the benchmark range is the 95% prediction interval.

Bivariate plots and Confidence ellipses

To assess correlation of RT *Candida* with candidemia incidence, the logit transformed data was assessed by two methods; a 95% prediction ellipse [138- 140], and linear regression. The prediction ellipse method enables the correlation as observed in other studies to be benchmarked. The relationship between logit transformed RT *Candida* with year of publication was assessed using locally weighted regression and smoothing scatterplot (LOWESS) [141].

Statistical analysis

A regression model of RT *Candida* proportion was developed using GEE methods as these accommodate any intra-cluster correlation ('xtgee' command in STATA; release 12.0, STATA Corp., College Station, TX, USA). In this analysis, the predictor variables were the component group membership being either membership of a group from an observational study; a control group or; an intervention group; type of intervention under study; the use or non-use of topical placebo and, whether the mode of diagnosis of VAP required bronchoscopic sampling. As a sensitivity analysis the GEE regression model analysis was repeated limited to studies obtained from systematic reviews. In addition to the Poisson model, the GEE regression model was undertaken with a binomial as well as a negative binomial models as additional sensitivity tests.

Results.

Characteristics of the studies

Of the 113 studies identified by the search [1-113], 72 were sourced from 13 systematic reviews and a further 40 sourced from elsewhere (Table 1; Fig. 1). The majority of SDD studies were published in the 1990's and all but four studies of SDD were European in origin. Two studies were supplemented with data from published doctoral theses [76, 113] or related publications [142]. The studies are detailed in the Electronic Supplementary Material (ESM) file.

A total of 191 component groups were decanted from these 113 studies with 36 groups from observational studies (ESM file Table S1), 71 groups from studies of various non-TA methods of VAP prevention (ESM file Table S2), and 84 groups from studies of SDD having either a non-concurrent (ESM file Table S3) or concurrent design (ESM file Table S4). Eleven studies had more than one observational, control or intervention group. Two studies had both concurrent and non-concurrent control groups. Group wide risk factors for candidemia were identified in only six studies. Three SDD studies used a regimen not containing an anti-fungal [71, 111, 112].

***Candida* colonization**

A measure of *Candida* colonization not limited to patients with suspected VAP and not limited to respiratory sites was reported for 32 studies including 18 of the SDD studies (Table 1). There was a wide range in this incidence (Fig. S5 & S6) with the incidence among concurrent control ($p = 0.066$; Table S5) groups from studies of SDD being higher versus the incidence in the observational groups.

The incidence of *Candida* colonisation, at sites other than respiratory tract and not restricted to patients with suspected VAP together with candidemia incidence were available from 40 groups from studies of all types. There were too few groups to discern a significant relationship between these incidences or to generate a robust prediction ellipse using the non-TA studies (Fig. S5).

RT *Candida* incidence

The mean RT *Candida* incidence among the 36 observational groups is 1.3 (95% confidence interval; 0.9-1.8%) (ESM file Fig. S1). This is the RT *Candida* benchmark. There was no significant trend in RT *Candida* incidence by year of study publication and a LOWESS line is presented (Fig. 2). Twenty-three of the 32 control groups of the concurrent control design studies were above this LOWESS line. The mean RT *Candida* incidence among the control groups was significantly higher than in the intervention groups from concurrent design SDD studies ($p = 0.001$; Fig. S4).

The RT *Candida* incidence was highest amongst the concurrent control groups of the SDD studies versus other types of component group (Fig. 3, ESM file Fig. S1-S4). The effect of membership of the various categories of component group on RT *Candida* were examined in GEE models of RT *Candida* together other group level variables (Table 2). The effect of membership of a concurrent control group of an SDD study was significant ($p=0.021$). The group wide presence of candidemia risk factors ($p = 0.001$) and the proportion of admissions for trauma ($p = 0.004$) were also significant factors in the model.

Candidemia

The incidence of candidemia was reported for 101 of the component groups (Table 1, Fig. S7). The incidence among concurrent control ($p = 0.024$) groups from studies of SDD were higher versus the incidence in the observational groups.

Both candidemia incidence and RT Candida incidence data were available from 19 groups from either observational studies or from studies of non-TA methods (Fig. 4a). The scatterplot presenting the bivariate relationship among these 19 groups, together with the linear regression line and a 95% prediction ellipse is shown using logit scales for each axis (Fig. 4a). This linear regression and prediction ellipse are in turn used to benchmark the groups from the studies of SDD (Fig. 4a-c). Whilst most of control groups from studies of SDD with a non-concurrent (Fig. 4b) and concurrent design (Fig. 4c) are within this benchmark prediction ellipse, shift to the right and upward is apparent for the control groups in the latter plot (Fig. 4c).

Discussion

This is a meta-analysis of the incidence of respiratory tract colonization with *Candida* (RT *Candida*) among ICU patients receiving mechanical ventilation within studies in the literature. This analysis has examined the relationship between RT *Candida* and candida colonization at other sites and also with candidemia as well as the relative importance of selective digestive decontamination (SDD) versus other candidate risk factors towards it. Only 45 of the studies are common to this meta-analysis and to the previous meta-analysis of candidemia [121]. This previous meta-analysis [121] was not restricted to the patient population receiving mechanical ventilation and had included a higher proportion of studies with group wide risk factors for candidemia (25 of the 103 studies [121]) versus only six of the 113 studies included here. As a consequence, there is a lower incidence of candidemia among the studies here versus previously [121]. However, even within this differently selected set of studies, the incidence of candidemia is again found to be higher among the control groups of SDD studies with a concurrent design than any other type of component group (Table 1).

There is a higher incidence of both *Candida* colonization at respiratory (RT candida) and other sites among the control groups of SDD studies with a concurrent design versus other groups (Table 1). This higher incidence of RT candida cannot be explained by year of publication (Fig. 2), nor in regression models that include the group wide presence of risk factors for candidemia or proportion of trauma admissions or mode of respiratory sampling (Table 2).

There is a correlation between candidemia and RT *Candida* among the studies here for which data is available (Fig. 4). However the relationship between RT *Candida* and candidemia is more complex than a simple linear correlation for the following reasons. Candidemia, with an incidence of approximately 1% amongst ICU patients [121], is a rare outcome and studies with fewer than 100 patients may have one or no cases [143-149]. The relationship described here is at the group level rather than at the patient level. In relation to non-respiratory *Candida* colonization, the patient level association has recently been examined in a multi-center study [150]. The relative risk for invasive candidiasis in the mechanically ventilated ICU patient population differs for throat, perineum and urine sites of colonization and also for different sampling time points [150]. Measures of non-respiratory *Candida* colonization among the studies here were poorly documented in relation to exact sites and timings and in any case was available from less than half of the studies surveyed.

It should be noted that the clinical significance of RT *Candida* is unclear [151-157] and current consensus guidelines recommend against its specific treatment in the absence of either clear histological evidence for pulmonary infection, which is rare [147-149], or evidence of invasive disease [114, 115]. However, *Candida* colonization continues to remain of interest from both the individual and the population perspective.

At the level of the individual, the clinical significance remains unclear with conflicting results of studies of *Candida* colonization of the respiratory tract among ICU patients. Some investigators have found that *Candida* colonization of the respiratory tract is associated with a worse outcome [151] in association with evidence of increased systemic inflammation [152]. However a subsequent pilot study of antifungal therapy for RT

candida did not find sufficient evidence of benefit to justify proceeding to a full scale controlled trial [153]. By contrast, other workers have not found an association with a higher mortality risk [145, 154] in ICU patients even though there were higher disease severity scores or degree of organ dysfunction at ICU admission. Moreover no apparent outcome benefit associated with the use of empiric systemic anti-fungal therapy in this patient group was found in either this study [154] or in a large multi-center study [155].

From the population perspective, *Candida* colonization is an important constituent of the ICU microbiome. RT candida could increase the risk for co-infection with antibiotic resistant bacteria in the airway [156] through molecular interactions with bacterial pathogens [117] for which anti-fungal therapy may be protective [118].

RT Candida has potential use as a more readily available indicator for benchmarking *Candida* colonization incidence in the patient group receiving mechanical ventilation. RT Candida is used here for this purpose so as to benchmark *Candida* colonization across different studies that have examined a variety of interventions whether using TA based regimens such as SDD or non-TA based methods for VAP prevention.

The effect of SDD on Candida colonization is unclear. On the one hand, SDD as a regimen comprising topical antibiotic and anti-fungal agents appears to be protective against fungal colonization, infection and possibly even mortality [119,120]. Indeed the protection derived by SDD appears to outperform that obtained using azole antifungal prophylaxis in this patient group [120]. On the other hand, this protection is not apparent in the largest study which had a non-concurrent design [157]. Moreover, SDD may have complex effects on the ICU microbiome. Indeed, in the first SDD study [74, 142] it was asked whether this

indirect effect of SDD might confound any attempt to estimate the direct effects using a conventional concurrent study design.

An uncalibrated analysis of the available *Candida* colonization data, whether as RT candida or as *Candida* colonization not restricted to respiratory sites and not restricted to patients with suspected VAP, are consistent with what appears to be a near halving in colonization incidences, as implied in the meta-analyses of the concurrent design SDD studies [119, 120]. However on closer scrutiny and using the RT candida benchmark for calibration, the true impact of SDD on the incidences of *Candida* colonization as well as on candidemia would appear to be a near doubling amongst the concurrent control groups of SDD studies (Table 1). This occurs presumably as a result of an indirect contextual effect through inapparent cross infection [158]. By contrast, the effect of SDD on RT candida in studies that are non-concurrent is insignificant (table 2), as observed elsewhere [157].

It is not the intention here to examine the substantial number of different SDD regimens but rather the component groups from the two broad categories of TA and non-TA studies. In any case, it should be noted that complete *Candida* decolonization using SDD is difficult to achieve [159, 160]. Two recent studies of ICU patients that were colonized with *Candida* and were receiving SDD provided conflicting evidence that the administration of nebulised amphotericin additional to SDD might confer clinical benefit [159] versus harm [160]. Of note in both studies, the time to achieve 50% decolonization with the addition of nebulised amphotericin to the standard SDD regime was five days in both studies. By contrast, among a multi-center study of 3000 ICU patients colonized with *Candida*

receiving routine systemic antifungal therapy with a mean ICU stay of 5 days, typically between 40 and 50% remain colonized on ICU discharge [161].

There are four specific challenges in undertaking an analysis of RT Candida. The potential for transmission of *Candida* between control and intervention group patients in the same study renders the presumption of independence of RT Candida events untenable [162].

Second, for most SDD studies the primary end point was VAP occurrence and RT Candida was an occasional secondary end point. How studies with zero RT Candida events are optimally included in any analysis is important to the conclusions. Studies with zero RT Candida events should not be overlooked as they provide potential evidence against a contextual effect. However, the majority of the SDD studies were smaller than 60 patients and, being a rare event (<2% in most studies), a zero RT Candida event rate is unsurprising. As a consequence, the upper 95% confidence intervals for these groups are non-trivial in caterpillar plots (Fig S1-S4). Note that for a group of size $N=60$ with zero events the upper 95% confidence can be approximated by the 'rule of three' as 5% ($= 3/N$) [163].

Thirdly, to quantify a contextual effect requires a calibration to a benchmark range derived using for reference data from studies from comparable target populations. The final issue is one of validity: does RT Candida correlate with a clinically relevant and commonly reported end point?

To deal with the first and third of these challenges, GEE based analytic strategies have been used here to model the RT Candida of both control and intervention groups of all

studies within a single analytic model as a statistical calibration (Table 2). There is an upward dispersion in RT Candida incidence among concurrent control groups from SDD studies away from this benchmark (Fig. 3). This upward dispersion is apparent in the GEE models as positive coefficients in association with membership of concurrent control groups within studies of SDD/SOD (Table 2).

To deal with the second and third issues, the continuity correction has been used to enable zero event groups to be represented on the logit scale which enables several types of graphical display for the purposes of a visual calibration (Figs. S1-4; Fig. 3). Moreover the validity issue is able to be addressed through an examination of the bivariate relationship between RT candida and candidemia (Figs. 4a-c). The visual analysis of the bivariate relationship is aided by the use of a 95% prediction ellipse in the plots, a method which is better suited to this purpose than linear regression [138-141]. All of these visual displays dramatically reveal that the component groups of all types, with the exception of those concurrent control groups from studies of SDD, each have a distribution similar to the observational groups from which the benchmark was derived. Strikingly even the distribution of the intervention groups of the SDD studies are similar to those from which the benchmark was derived. This would imply that any apparent effect of SDD on Candida colonization and Candidemia within concurrent control design studies is not explainable as simply a direct anti-fungal prevention effect occurring within the intervention group (Fig. S7).

There are several limitations to this study. This is an analysis at the group level and is unable to take account of patient specific risk factors for RT Candida. For example, the usage of empiric (non-protocolized) antifungal therapy in each study is an important

unknown as non-use may account for vulnerability to RT Candida at the individual level. However, it is unlikely that such unidentified patient level risk factors would be able to account for the discrepancies noted here. Such a putative patient level risk factor would need to be a consistently strong risk factor for RT Candida across all the studies and yet also be profoundly unevenly distributed, predominating in the groups of the SDD studies versus other groups within the broader evidence base examined here.

Another limitation is the imprecision associated with the diagnosis of VAP which may lead to the potential for observer detection bias of RT Candida. That the mode of VAP diagnosis and the use of topical placebo were not significant factors in the regression model (table 2) implies that this bias is likely to be minimal. Moreover, topical placebo use can be taken as a surrogate indicator of a study that was observer blinded. A further limitation is the question of non-reporting of RT Candida amongst potentially eligible studies. However, the correlation between RT Candida and candidemia provides some validation at least amongst those studies for which both data were available.

It is never possible to be certain that every relevant study has been obtained in a literature search or that the search has been truly adequate. Restricting the analysis to those studies obtained from systematic reviews attempts to provide the basis for an analysis of data derived through an independent and transparent search. That the findings of such a restricted analysis are similar to the full analysis would imply that the search has been adequate and that the number of missing studies required to alter the findings would need to be substantial.

Conclusion

The RT Candida incidence within observational groups of mechanically ventilated patients is 1.3% (this is the RT Candida benchmark). The incidence of RT candida and candidemia are correlated. There is insufficient information to discern how closely *Candida* colonization at other sites is correlated with candidemia. At the group level, the presence of candidemia risk factors, the proportion of trauma admissions and membership of a concurrent control group within an SDD study are each risk factors for RT Candida. The apparent protection against *Candida* colonization from the use of SDD appears spurious as the incidence of both RT candida and colonization at other sites is higher among concurrent control groups of SDD studies than among observational and indeed other types of component group. These observations, as with similar observations for VAP [123], candidemia [121] and bacteremia [122] incidences among these studies, are paradoxical. Apart from major publication bias, or the effect of any major and as yet unidentified and mal-distributed patient level risk factors for RT Candida, these profound discrepancies indicate a major contextual hazard associated with the topical antibiotic component of SDD on RT Candida within studies with concurrent controls. These increased incidences would be inapparent within individual SDD studies examined in isolation [158].

Abbreviations;

ICU, Intensive Care Unit; MV, Mechanical Ventilation ; SDD, selective Digestive Decontamination; VAP, Ventilator associated pneumonia; RT Candida, *Candida* among patients with Ventilator associated pneumonia

441 Additional material

442 ESM file: RT Candida data for observational studies (Table S1), studies of non-TA-based
443 methods of VAP prevention (Table S2), studies of SDD with non-concurrent
444 groups (Table S3) and studies of SDD with concurrent groups (Table S4).
445 Caterpillar and other plots of RT Candida data (Fig. S1-S7).
446

Competing interests

James Hurley declares that he has no competing interests.

Author contributions

As sole author, JH produced the design of the study, performed the statistical analysis and wrote the manuscript. JH read and approved the final manuscript.

Compliance with Ethical Standards

Sources of funding: This work was supported by the Australian Government Department of Health and Ageing through the Rural Clinical Training and Support (RCTS) program. The funding agency had no role in the preparation of the manuscript nor its approval for submission.

Disclosure of potential conflicts of interest: The author declares that he has no conflict of interest.

Ethical approval: This article does not contain any studies with human participants performed by the author.

References

1. Antonelli M, Moro ML, Capelli O, et al (1994) Risk factors for early onset pneumonia in trauma patients. *Chest* 105:224-228
2. Bercault N, Boulain T (2001) Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. *Crit Care Med* 29:2303-2309
3. Boots RJ, Phillips GE, George N, Faoagali JL (2008) Surveillance culture utility and safety using low-volume blind bronchoalveolar lavage in the diagnosis of ventilator-associated pneumonia. *Respirology* 13:87-96
4. Bregeon F, Papazian L, Visconti A, Gregoire R, Thirion X, Gouin F (1997) Relationship of microbiologic diagnostic criteria to morbidity and mortality in patients with ventilator-associated pneumonia. *JAMA* 277: 655-662
5. Cade JF, McOwat E, Siganporia R, Keighley C, Presneill J, Sinickas V (1992) Uncertain relevance of gastric colonization in the seriously ill. *Intensive Care Med* 18:210-217
6. Cavalcanti M, Ferrer M, Ferrer R, et al (2006) Risk and prognostic factors of ventilator-associated pneumonia in trauma patients. *Crit Care Med* 34:1067-1072
7. Cardenosa Cendrero JA, Sole-Violan J, Bordes Benitez A, et al (1999) Role of different routes of tracheal colonization in the development of pneumonia in patients receiving mechanical ventilation. *Chest* 116:462-470
8. Chastre J, Trouillet JL, Vuagnat A, et al (1998) Nosocomial pneumonia in patients with acute respiratory distress syndrome. *Am J Respir Crit Care Med* 157:1165-1172
9. Chevret S, Hemmer M, Carlet J, et al (1993) Incidence and risk factors of pneumonia acquired in intensive care units. Results from a multicenter prospective study on 996 patients. European Cooperative Group on Nosocomial Pneumonia. *Intensive Care Med* 19:256-264
10. Craven DE, Kunches LM, Lichtenberg DA, Kollisch NR, Barry MA, Heeren TC, McCabe WR (1988) Nosocomial infection and fatality in medical and surgical intensive care unit patients. *Arch Intern Med* 148:1161-1168
11. Daschner F, Kappstein I, Schuster F, et al (1988) Influence of disposable ('Conchapak') and reusable humidifying systems on the incidence of ventilation pneumonia. *J Hosp Infect* 11:161-168
12. de Latorre FJ, Pont T, Ferrer A, et al (1995) Pattern of tracheal colonization during mechanical ventilation. *Am J Respir Crit Care Med* 152:1028-1033
13. Ensminger SA, Wright RS, Baddour LM, Afess B (2006) Suspected ventilator-associated pneumonia in cardiac patients admitted to the coronary care unit. *Mayo Clin Proc* 81:32-35
14. Ewig S, Torres A, El-Ebiary M, et al (1999) Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated pneumonia. *Am J Respir Crit Care Med* 159:188-198
15. George DL, Falk PS, Wunderink RG, Leeper Jr KV, Meduri GU, Steere EL, Glen Mayhall C (1998) Epidemiology of ventilator-acquired pneumonia based on protected bronchoscopic sampling. *Am J Respir Crit Care Med* 158:1839-1847

16. Gursel G, Aydogdu M, Nadir Ozis T, Tasyurek S (2010) Comparison of the value of initial and serial endotracheal aspirate surveillance cultures in predicting the causative pathogen of ventilator-associated pneumonia. *Scandinavian J Infect Dis* 42:341-346
17. Hugonnet S, Uçkay I, Pittet D (2007) Staffing level: a determinant of late-onset ventilator-associated pneumonia. *Crit Care* 11(4):R80
18. Ibrahim EH, Ward S, Sherman G, Kollef MH (2000) A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. *Chest* 117:1434-1442
19. Kautzky S, Staudinger T, Presterl E (2014) Invasive *Candida* infections in patients of a medical intensive care unit. *Wiener klinische Wochenschrift* 127:1-11
20. Kollef MH, Vlasnik J, Sharpless L, Pasque C, Murphy D, Fraser V (1997) Scheduled change of antibiotic classes: A strategy to decrease the incidence of ventilator-associated pneumonia. *Am J Respir Crit Care Med* 156:1040-1048
21. Luna CM, Blanzaco D, Niederman MS, et al (2003) Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. *Crit Care Med* 31:676-682
22. Magnason S, Kristinsson KG, Stefansson T, Erlendsdottir H, Jonsdottir K, Kristjansson M, Gudmundsson S (2008) Risk factors and outcome in ICU-acquired infections. *Acta Anaesthesiologica Scandinavica* 52:1238-1245
23. Mahul P, Auboyer C, Jospe R, Ros A, Guerin C, el Khouri Z, Galliez M, Dumont A, Gaudin O (1992) Prevention of nosocomial pneumonia in intubated patients respective role of mechanical subglottic secretions drainage and stress ulcer prophylaxis. *Intensive Care Med* 18:20-25
24. Memish ZA, Cunningham G, Oni GA, et al (2000) The incidence and risk factors of ventilator-associated pneumonia in a Riyadh hospital. *Infect Control Hosp Epidemiol* 21:271-273
25. Moine P, Timsit JF, De Lasseance A, et al (2002) Mortality associated with late-onset pneumonia in the intensive care unit: results of a multi-center cohort study. *Intensive Care Med* 28:154-163
26. Potgieter PD, Linton DM, Oliver S, Forder AA (1987) Nosocomial infections in a respiratory intensive care unit. *Crit Care Med* 15:495-498
27. Rello J, Quintana E, Ausina V, et al (1991) Incidence, etiology, and outcome of nosocomial pneumonia in mechanically ventilated patients. *Chest* 100:439-444
28. Rello J, Ausina V, Castella J, et al (1992) Nosocomial respiratory tract infections in multiple trauma patients. Influence of level of consciousness with implications for therapy. *Chest* 102:525-529
29. Rello J, Lorente C, Diaz E, et al (2003) Incidence, etiology, and outcome of nosocomial pneumonia in ICU patients requiring percutaneous tracheotomy for mechanical ventilation. *Chest* 124:2239-2243
30. Resende MM, Monteiro SG, Callegari B, Figueiredo PM, Monteiro CR, Monteiro-Neto V (2013) Epidemiology and outcomes of ventilator-associated pneumonia in northern Brazil: an analytical descriptive prospective cohort study. *BMC infect Dis* 13(1): 119

- 555 31. Reusser P, Zimmerli W, Scheidegger D, Marbet GA, Buser M, Gyr K (1989) Role of
556 gastric colonization in nosocomial infections and endotoxemia: a prospective study in
557 neurosurgical patients on mechanical ventilation. *J Infect Dis* 160:414-421
- 558 32. Ruiz-Santana S, Garcia Jimenez A, Esteban A, et al (1987) ICU pneumonias: a multi-
559 institutional study. *Crit Care Med* 15:930-932
- 560 33. Salata RA, Lederman MM, Shlaes DM, Jacobs MR, Eckstein E, Tweardy D, Toossi Z,
561 Chmielewski R, Marino J, King CH (1987) Diagnosis of nosocomial pneumonia in
562 intubated, intensive care unit patients. *Am Rev Respir Dis* 135:426-432
- 563 34. Shahin J, Bielinski M, Guichon C, Flemming C, Kristof AS (2013) Suspected
564 ventilator-associated respiratory infection in severely ill patients: a prospective
565 observational study. *Crit Care* 17(5): R251
- 566 35. Xie DS, Xiong W, Lai RP, Liu L, Gan XM, Wang XH, Nie SF (2011) Ventilator-
567 associated pneumonia in intensive care units in Hubei Province, China: a multicentre
568 prospective cohort survey. *J Hosp Infect* 78(4): 284-288
- 569 36. Acosta-Escribano J, Fernández-Vivas M, Carmona TG, Caturla-Such J, Garcia-
570 Martinez M, Menendez-Mainer A, Sanchez-Payá J (2010) Gastric versus transpyloric
571 feeding in severe traumatic brain injury: a prospective, randomized trial. *Intensive Care*
572 *Med* 36:1532-1539
- 573 37. Bellissimo-Rodrigues WT, Meneguetti MG, Gaspar GG, Nicolini EA, Auxiliadora-
574 Martins M, Basile-Filho A, Bellissimo-Rodrigues F (2014) Effectiveness of a Dental
575 Care Intervention in the Prevention of Lower Respiratory Tract Nosocomial Infections
576 among Intensive Care Patients: A Randomized Clinical Trial. *Infect Control Hosp*
577 *Epidemiol* 35:1342-1348
- 578 38. Caruso P, Denari S, Ruiz SA, Demarzo SE, Deheinzelin D (2009) Saline instillation
579 before tracheal suctioning decreases the incidence of ventilator-associated pneumonia.
580 *Crit Care Med* 37:32-38
- 581 39. Cook D, Guyatt G, Marshall J, et al (1998) A comparison of sucralfate and ranitidine
582 for the prevention of upper gastrointestinal bleeding in patients requiring mechanical
583 ventilation. Canadian Critical Care Trials Group. *N Engl J Med* 338:791-797
- 584 40. Daumal F, Colpart E, Manoury B, Mariani M, Daumal M (1999) Changing heat and
585 moisture exchangers every 48 hours does not increase the incidence of nosocomial
586 pneumonia. *Infection Control* 20(05), 347-349
- 587 41. Drakulovic MB, Torres A, Bauer TT, Nicolas JM, Nogué S, Ferrer M (1999) Supine
588 body position as a risk factor for nosocomial pneumonia in mechanically ventilated
589 patients: a randomised trial. *Lancet* 354(9193):1851-1858
- 590 42. Driks MR, Craven DE, Celli BR, et al (1987) Nosocomial pneumonia in intubated
591 patients given sucralfate as compared with antacids or histamine type 2 blockers. The
592 role of gastric colonization. *N Engl J Med* 317:1376-1382
- 593 43. Fourrier FE, Cau-Pottier H, Boutigny M, Roussel-Delvallez M, Jourdain, Chopin C
594 (2000) Effects of dental plaque antiseptic decontamination on bacterial colonization
595 and nosocomial infections in critically ill patients. *Intensive Care Med* 26:1239-1247
- 596 44. Fourrier F, Dubois D, Pronnier P, Herbecq P, Leroy O, Desmettre T, Roussel-Delvallez
597 M (2005) Effect of gingival and dental plaque antiseptic decontamination on

nosocomial infections acquired in the intensive care unit a double-blind placebo-controlled multicenter study. *Crit Care Med* 33:1728-1735

45. Giglio M, Caggiano G, Dalfino L, Brienza N, Alicino I, Sgobio A, Favale A, Puntillo F (2012) Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomised clinical trial. *Crit Care* 16(2):R57

46. Heyland DK, Cook DJ, Schoenfeld PS, Frietag A, Varon J, Wood G (1999) The effect of acidified enteral feeds on gastric colonization in critically ill patients: results of a multicenter randomized trial. Canadian Critical Care Trials Group. *Crit Care Med* 27:2399-2406

47. Holzapfel L, Chevret S, Madinier G, Ohen F, Demingeon G, Couprie A, Chaudet M (1993) Influence of long-term oro- or nasotracheal intubation on nosocomial maxillary sinusitis and pneumonia: results of a prospective, randomized, clinical trial. *Crit Care Med* 21:1132-1138

48. Holzapfel L, Chastang C, Demingeon G, Bohe J, Piralla B, Couprie A (1999) A randomized study assessing the systematic search for maxillary sinusitis in nasotracheally mechanically ventilated patients. Influence of nosocomial maxillary sinusitis on the occurrence of ventilator-associated pneumonia. *Am J Respir Crit Care Med* 159:695-701

49. Koeman M, van der Ven AJ, Hak E, et al (2006) Oral decontamination with chlorhexidine reduces the incidence of ventilator-associated pneumonia. *Am J Respir Crit Care Med* 173:1348-1355

50. Kollef MH, Afessa B, Anzueto A, Veremakis C, Kerr KM, Margolis BD, Schinner R (2008) Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. *JAMA* 300(7):805-813

51. Lacherade JC, Auburtin M, Cerf C, et al (2005) Impact of humidification systems on ventilator-associated pneumonia: a randomized multicenter trial. *Am J Respir Crit Care Med* 172:1276-1282

52. Lorente L, Lecuona M, Malaga J, et al (2003) Bacterial filters in respiratory circuits: an unnecessary cost? *Crit Care Med* 31:2126-2130

53. Lorente L, Lecuona M, Galvan R, et al (2004) Periodically changing ventilator circuits is not necessary to prevent ventilator-associated pneumonia when a heat and moisture exchanger is used. *Infect Control Hosp Epidemiol* 25:1077-1082

54. Lorente L, Lecuona M, Martin MM, et al (2005) Ventilator-associated pneumonia using a closed versus an open tracheal suction system. *Crit Care Med* 33:115-119

55. Lorente L, Lecuona M, Jimenez A, et al (2006) Tracheal suction by closed system without daily change versus open system. *Intensive Care Med* 32:538-544

56. Lorente L, Lecuona M, Jimenez A, Mora ML, Sierra A (2006) Ventilator-associated pneumonia using a heated humidifier or a heat and moisture exchanger: a randomized controlled trial [ISRCTN88724583]. *Crit Care* 10:R116

57. Lorente L, Lecuona M, Jimenez A, Mora ML, Sierra (2007) Influence of an endotracheal tube with polyurethane cuff and subglottic secretion drainage on pneumonia. *Am J Respir Crit Care Med* 176:1079-1083

- 640 58. Lorente L, Lecuona M, Jiménez A, Palmero S, Pastor E, Lafuente N, Ramos MJ, Mora
641 ML, Sierra A (2012) Ventilator-associated pneumonia with or without toothbrushing a
642 randomized controlled trial. *Eur J Clin Microbiol Infect Dis* 31:1-9
- 643 59. Martin LF, Booth FV, Karlstadt RG, et al (1993) Continuous intravenous cimetidine
644 decreases stress-related upper gastrointestinal hemorrhage without promoting
645 pneumonia. *Crit Care Med* 21:19-30
- 646 60. Mori H, Hirasawa H, Oda S, Shiga H, Matsuda K, Nakamura M (2006) Oral care
647 reduces incidence of ventilator-associated pneumonia in ICU populations. *Intensive*
648 *Care Med* 32(2):230-236
- 649 61. Morrow LE, Kollef MH, Casale TB (2010) Probiotic prophylaxis of ventilator-
650 associated pneumonia: a blinded, randomized, controlled trial. *Am J Respir Crit Care*
651 *Med* 182:1058-1064
- 652 62. Normand S, François B, Dardé ML, Bouteille B, Bonnivard M, Preux PM, Vignon P
653 (2005) Oral nystatin prophylaxis of *Candida* spp. colonization in ventilated critically ill
654 patients. *Intensive Care Med* 31(11) :1508-1513
- 655 63. Pickworth KK, Falcone RE, Hoozeboom JE, et al (1993) Occurrence of nosocomial
656 pneumonia in mechanically ventilated trauma patients: a comparison of sucralfate and
657 ranitidine. *Crit Care Med* 21:1856-1862
- 658 64. Pneumatikos I, Konstantonis D, Tsagaris I, et al (2006) Prevention of nosocomial
659 maxillary sinusitis in the ICU: the effects of topically applied alpha-adrenergic agonists
660 and corticosteroids. *Intensive Care Med* 32:532-537
- 661 65. Segers P, Speekenbrink RG, Ubbink DT, van Ogtrop ML, Bas A (2006) Prevention of
662 nosocomial infection in cardiac surgery by decontamination of the nasopharynx and
663 oropharynx with chlorhexidine gluconate: a randomized controlled
664 trial. *JAMA* 296(20), 2460-2466.
- 665 66. Sirvent JM, Torres A, El-Ebiary M, Castro P, de Batlle J, Bonet A (1997) Protective
666 effect of intravenously administered cefuroxime against nosocomial pneumonia in
667 patients with structural coma. *Am J Respir Crit Care Med* 155:1729-1734
- 668 67. Smulders K, van der Hoeven H, Weers-Pothoff I, Vandenbroucke-Grauls C (2002) A
669 randomized clinical trial of intermittent subglottic secretion drainage in patients
670 receiving mechanical ventilation. *Chest* 121:858-862
- 671 68. Staudinger T, Bojic A, Holzinger U, Meyer B, Rohwer M, Mallner F, Locker GJ
672 (2010) Continuous lateral rotation therapy to prevent ventilator-associated
673 pneumonia *Crit Care Med* 38(2):486-490
- 674 69. Thomachot L, Viviani X, Arnaud S, Boisson C, Martin CD (1998) Comparing two
675 heat and moisture exchangers, one hydrophobic and one hygroscopic, on humidifying
676 efficacy and the rate of nosocomial pneumonia. *Chest* 114:1383-1389
- 677 70. Thomachot L, Vialet R, Arnaud S, et al (1999) Do the components of heat and
678 moisture exchanger filters affect humidifying efficacy and the incidence of nosocomial
679 pneumonia? *Crit Care Med* 27:923-928
- 680 71. Bergmans DC, Bonten MJ, Gaillard CA, et al (2001) Prevention of ventilator-
681 associated pneumonia by oral decontamination: a prospective, randomized, double-
682 blind, placebo-controlled study. *Am J Respir Crit Care Med* 164:382-388

72. Camus C, Salomon S, Bouchigny C, Gacouin A, Lavoué S, Donnio PY, Bellissant E (2014) Short-Term Decline in All-Cause Acquired Infections With the Routine Use of a Decontamination Regimen Combining Topical Polymyxin, Tobramycin, and Amphotericin B With Mupirocin and Chlorhexidine in the ICU: A Single-Center Experience. *Crit Care Med* 42:1121-1130
73. Hartenauer U, Thulig B, Diemer W, Lawin P, Fegeler W, Kehrel R, Ritzerfeld W (1991) Effect of selective flora suppression on colonization, infection, and mortality in critically ill patients: a one-year, prospective consecutive study. *Crit Care Med* 19:463-473
74. Stoutenbeek CP, van Saene HK, Miranda DR, Zandstra DF, Langrehr D (1987) The effect of oropharyngeal decontamination using topical nonabsorbable antibiotics on the incidence of nosocomial respiratory tract infections in multiple trauma patients. *J Trauma* 27:357-364
75. Winter R, Humphreys H, Pick A, et al (1992) A controlled trial of selective decontamination of the digestive tract in intensive care and its effect on nosocomial infection. *J Antimicrob Chemother* 30:73-87
76. David A (2007) Infektionen und Keimspektrum nach einer Dekade der Selektiven Darmdekontamination (SDD) in der operativen Intensivmedizin. [Infections and germ spectrum after a decade of Selective intestinal decontamination (SDD) in the surgical intensive care medicine] Dissertation, Universitätsklinikum Münster. <http://nbn-resolving.de/urn:nbn:de:hbz:6-08599456972>. Accessed 10 November 2015
77. Hjortrup A, Rasmussen A, Hansen BA, Hoiby N, Heslet L, Moesgaard F, Kirkegaard P (1997) Early bacterial and fungal infections in liver transplantation after oral selective bowel decontamination. *Transplantation proceedings* 29:3106-3110
78. Nardi G, Di Silvestre A, De Monte A, Massarutti D, Proietti A, Troncon MG, Zussino M (2001) Reduction in gram-positive pneumonia and antibiotic consumption following the use of a SDD protocol including nasal and oral mupirocin. *Eur J Emerg Med* 8:203-214
79. Silvestri L, Bragadin CM, Milanese M, Gregori D, Consales C, Gullo A, van Saene HFK (1999) Are most ICU infections really nosocomial? A prospective observational cohort study in mechanically ventilated patients. *J Hosp Infect* 42:125-133
80. Steffen R, Reinhartz O, Blumhardt G, Bechstein WO, Raakow R, Langrehr JM, Neuhaus P (1994) Bacterial and fungal colonization and infections using oral selective bowel decontamination in orthotopic liver transplantations. *Transpl Int* 7(2):101-108
81. Aerdts SJ, van Dalen R, Clasener HA, Festen J, van Lier HJ, Vollaard EJ (1991) Antibiotic prophylaxis of respiratory tract infection in mechanically ventilated patients. A prospective, blinded, randomized trial of the effect of a novel regimen. *Chest* 100:783-791
82. Bion JF, Badger I, Crosby HA, Hutchings P, Kong KL, Baker J, Hutton P, McMaster P, Buckels JA, Elliott TSJ (1994) Selective decontamination of the digestive tract reduces gram-negative pulmonary colonization but not systemic endotoxemia in patients undergoing elective liver transplantation. *Crit Care Med* 22:40-49
83. Blair P, Rowlands BJ, Lowry K, Webb H, Armstrong P, Smilie J (1991) Selective decontamination of the digestive tract: a stratified, randomized, prospective study in a mixed intensive care unit. *Surgery* 110:303-309

84. Cerra FB, Maddaus MA, Dunn DL, Wells CL, Konstantinides NN, Lehmann SL, Mann HJ (1992) Selective gut decontamination reduces nosocomial infections and length of stay but not mortality or organ failure in surgical intensive care unit patients. *Arch Surg* 127:163-167
85. de La Cal MA, Cerda E, Garcia-Hierro P, Van Saene HK, Gómez-Santos D, Negro E, Lorente JA (2005) Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo-controlled, double-blind trial. *Ann Surg* 241:424-430
86. Ferrer M, Torres A, Gonzalez J, Puig de la Bellacasa J, el-Ebiary M, Roca M, Gatell JM, Rodriguez-Roisin R (1994) Utility of selective digestive decontamination in mechanically ventilated patients. *Ann Intern Med* 120:389-395
87. Flaherty J, Nathan C, Kabins SA, Weinstein RA (1990) Pilot trial of selective decontamination for prevention of bacterial infection in an intensive care unit. *J Infect Dis* 162:1393-1397
88. Gaussorgues P, Salord M, Sirodot S, Tigaud S, Cagnin S, Gerard M, Robert D (1991) Efficiency of selective decontamination of the digestive tract on the occurrence of nosocomial bacteremia in patients on mechanical ventilation receiving betamimetic therapy. *Réan Soins Intens Méd Urg* 7:169-174
89. Georges B, Mazerolles M, Decun J-F, Rouge P, Pomies S, Cougot P (1994) Décontamination digestive sélective résultats d'une étude chez le polytraumatisé. *Réanimation Soins Intensifs Médecin d'Urgence* 3:621-627
90. Hünefeld G (1988) [A clinical study of selective gut decolonization in 204 long-term ventilated intensive care patients undergoing abdominal and accident surgery]. *Anaesthesiologie und Reanimation* 14:131-153
91. Jacobs S, Foweraker JE, Roberts SE (1992) Effectiveness of selective decontamination of the digestive tract (SDD) in an ICU with a policy encouraging a low gastric pH. *Clin Intensive Med* 3:52-58
92. Kerver AJ, Rommes JH, Mevissen-Verhage EA, Hulstaert PF, Vos A, Verhoef J, Wittebol P (1988) Prevention of colonization and infection in critically ill patients: a prospective randomized study. *Crit Care Med* 16:1087-1093
93. Kollef M, Pittet D, Sanchez Garcia M, et al (2006) A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia. *Am J Respir Crit Care Med* 173:91-97
94. Korinek AM, Laisne MJ, Nicolas MH, Raskine L, Deroin V, Sanson-Lepors MJ (1993) Selective decontamination of the digestive tract in neurosurgical intensive care unit patients: a double-blind, randomized, placebo-controlled study. *Crit Care Med* 21:1466-1473
95. Laggner AN, Tryba M, Georgopoulos A, Lenz K, Grimm G, Graninger W, Schneeweiss B, Druml W (1994) Oropharyngeal decontamination with gentamicin for long-term ventilated patients on stress ulcer prophylaxis with sucralfate? *Wien Klin Wochenschr* 106:15-19
96. Palomar M, Alvarez-Lerma F, Jorda R, Bermejo B, Catalan Study Group of Nosocomial Pneumonia Prevention (1997) Prevention of nosocomial infection in mechanically ventilated patients: selective digestive decontamination versus sucralfate. *Clin Intens Care* 8:228-235

- 773 97. Pneumatikos I, Koulouras V, Nathanail C, Goe D, Nakos G (2002) Selective
774 decontamination of subglottic area in mechanically ventilated patients with multiple
775 trauma. *Intensive Care Med* 28:432-437
- 776 98. Quinio B, Albanese J, Bues-Charbit M, Viviani X, Martin C (1996) Selective
777 decontamination of the digestive tract in multiple trauma patients. A prospective
778 double-blind, randomized, placebo-controlled study. *Chest* 109:765-772
- 779 99. Rocha LA, Martin MJ, Pita S, Paz J, Seco C, Margusino L, Villanueva R, Duran MT
780 (1992) Prevention of nosocomial infection in critically ill patients by selective
781 decontamination of the digestive tract. A randomized, double blind, placebo-controlled
782 study. *Intensive Care Med* 18:398-404
- 783 100. Rolando N, Gimson A, Wade J, Philpott-Howard J, Casewell M, Williams R
784 (1993) Prospective controlled trial of selective parenteral and enteral antimicrobial
785 regimen in fulminant liver failure. *Hepatology* 17:196-201
- 786 101. Rolando N, Wade JJ, Stangou A, Gimson AE, Wendon J, Philpott-Howard J,
787 Williams R (1996) Prospective study comparing the efficacy of prophylactic parenteral
788 antimicrobials, with or without enteral decontamination, in patients with acute liver
789 failure. *Liver transplantation and surgery*. 2:8-13
- 790 102. Sanchez Garcia M, Cambronero Galache JA, Lopez Diaz J, Cerda Cerda E, Rubio
791 Blasco J, Gomez Aguinaga MA, Nunez Reiz A, Rogero Marin S, Onoro Canaveral JJ,
792 Sacristan del Castillo JA (1998) Effectiveness and cost of selective decontamination of
793 the digestive tract in critically ill intubated patients. A randomized, double-blind,
794 placebo-controlled, multicenter trial. *Am J Respir Crit Care Med* 158:908-916
- 795 103. Smith SD, Jackson RJ, Hannakan CJ, Wadowsky RM, Tzakis AG, Rowe MI
796 (1993) Selective decontamination in pediatric liver
797 transplants. *Transplantation* 55:1306-1308
- 798 104. Stoutenbeek CP, van Saene HKF, Little RA, Whitehead A (2007) The effect of
799 selective decontamination of the digestive tract on mortality in multiple trauma
800 patients: a multicenter randomized controlled trial. *Intensive Care Med* 33:261-270
- 801 105. Tetteroo GWM, Castelein A, Tilanus HW, Ince C, Bruining HA, Wagenvoort JHT
802 (1990) Selective decontamination to reduce gram-negative colonisation and infections
803 after oesophageal resection. *Lancet* 335:704-707
- 804 106. Ulrich C, Harinck-de Weerd JE, Bakker NC, Jacz K, Doornbos L, de Ridder VA
805 (1989) Selective decontamination of the digestive tract with norfloxacin in the
806 prevention of ICU-acquired infections: a prospective randomized study. *Intensive Care*
807 *Med* 15:424-431
- 808 107. Unertl K, Ruckdeschel G, Selbmann HK, et al (1987) Prevention of colonization
809 and respiratory infections in long-term ventilated patients by local antimicrobial
810 prophylaxis. *Intensive Care Med* 13:106-113
- 811 108. Verwaest C, Verhaegen J, Ferdinande P, Schetz M, Van den Berghe G, Verbist L,
812 Lauwers P (1997) Randomized, controlled trial of selective digestive decontamination
813 in 600 mechanically ventilated patients in a multidisciplinary intensive care unit. *Crit*
814 *Care Med* 25:63-71
- 815 109. Wiener J, Itokazu G, Nathan C, Kabins SA, Weinstein RA (1995) A randomized,
816 double-blind, placebo-controlled trial of selective digestive decontamination in a
817 medical-surgical intensive care unit. *Clin Infect Dis* 20:861-867

110. Zobel G, Kuttig M, Grubbauer HM, Semmelrock HJ, Thiel W (1991) Reduction of colonization and infection rate during pediatric intensive care by selective decontamination of the digestive tract. *Crit Care Med* 19:1242-1246
111. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D (2002) Prevention of severe *Candida* infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. *Intensive Care Med* 28:1708-1717
112. Garbino J, Pichard C, Pichna P, Pittet D, Lew D, Romand J (2004) Impact of enteral versus parenteral nutrition on the incidence of fungal infections: a retrospective study in ICU patients on mechanical ventilation with selective digestive decontamination. *Clinical Nutrition* 23:705-710
113. Verhaegen J (1992) Randomized study of selective digestive decontamination on colonization and prevention of infection in mechanically ventilated patients in the ICU. Dissertation, University Hospital, Leuven, Belgium
114. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Ullmann AJ (2012) ESCMID guideline for the diagnosis and management of *Candida* diseases 2012: non-neutropenic adult patients. *Clinical Microbiology Infection* 18(s7): 19-37
115. Torres A, Ewig S, Lode H, Carlet J, European HAP Working Group (2009) Defining, treating and preventing hospital acquired pneumonia: European perspective. *Intensive Care Med* 35(1): 9-29
116. Chastre J, Fagon JY (2002) Ventilator-associated pneumonia. *Am J Respir Crit Care Med* 165:867-903
117. Lindsay AK, Hogan DA (2015) *Candida albicans*: Molecular interactions with *Pseudomonas aeruginosa* and *Staphylococcus aureus*. *Fungal Biol Rev* 28:85-96
118. Nseir S, Jozefowicz E, Cavestri B, Sendid B, Di Pompeo C, Dewavrin F, Durocher A (2007) Impact of antifungal treatment on *Candida*–*Pseudomonas* interaction: a preliminary retrospective case–control study. *Intensive Care Med* 33(1):137-142
119. Silvestri L, Van Saene HK, Milanese M, Gregori D (2005) Impact of selective decontamination of the digestive tract on fungal carriage and infection: systematic review of randomized controlled trials. *Intensive Care Med* 31:898-910
120. van Till JO, van Ruler O, Lamme B, Weber RJ, Reitsma JB, Boermeester MA (2007) Single-drug therapy or selective decontamination of the digestive tract as antifungal prophylaxis in critically ill patients: a systematic review. *Crit Care* 11:R126
121. Hurley JC (2015) ICU-acquired candidemia within selective digestive decontamination studies: a meta-analysis *Intensive Care Med* 41:1877-1885
122. Hurley JC (2014) Topical antibiotics as a major contextual hazard toward bacteremia within selective digestive decontamination studies: a meta-analysis *BMC Infect Dis* 14:714
123. Hurley JC (2014) Ventilator Associated Pneumonia prevention methods using topical antibiotics: herd protection or herd peril? *Chest* 146(4): 890-898.
124. Melsen WG, Rovers MM, Bonten MJM (2009) Ventilator-associated pneumonia and mortality: A systematic review of observational studies. *Crit Care Med* 37: 2709–2718

- 862 125. Safdar N, Dezfulian C, Collard HR, Saint S (2005) Clinical and economic
863 consequences of ventilator-associated pneumonia: a systematic review. *Crit Care Med*
864 33: 2184–2193
- 865 126. Agrafiotis M, Siempos II, Ntaidou TK, Falagas ME (2011) Attributable mortality
866 of ventilator-associated pneumonia: a meta-analysis. *Intern J Tub Lung Dis* 15:1154-
867 1163
- 868 127. Messori A, Trippoli S, Vaiani M, Gorini M, Corrado A (2000) Bleeding and
869 pneumonia in intensive care patients given ranitidine and sucralfate for prevention of
870 stress ulcer: meta-analysis of randomised controlled trials. *BMJ* 321:1103–1106
- 871 128. Huang J, Cao Y, Liao C, Wu L, Gao F (2010) Effect of histamine-2-receptor
872 antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated
873 patients: a meta-analysis of 10 randomized controlled trials. *Crit Care* 14:R194
- 874 129. Alhazzani W, Almasoud A, Jaeschke R, Lo BW, Sindi A, Altayyar S, Fox-
875 Robichaud A (2013) Small bowel feeding and risk of pneumonia in adult critically ill
876 patients: a systematic review and meta-analysis of randomized trials. *Crit Care*
877 17:R127
- 878 130. Chan EY, Ruest A, Meade MO, Cook DJ (2007) Oral decontamination for
879 prevention of pneumonia in mechanically ventilated adults: systematic review and
880 meta-analysis. *BMJ* 334:889–900
- 881 131. Labeau SO, Van de Vyver K, Brusselaers N, Vogelaers D, Blot SI (2011)
882 Prevention of ventilator-associated pneumonia with oral antiseptics: a systematic
883 review and meta-analysis. *Lancet Infect Dis* 11:845-854
- 884 132. Liberati A, D'Amico R, Pifferi S, Torri V, Brazzi L, Parmelli E (2009) Antibiotic
885 prophylaxis to reduce respiratory tract infections and mortality in adults receiving
886 intensive care. *Cochrane Database Syst Rev* 4
- 887 133. Vandenbroucke-Grauls CM, Vandenbroucke JP (1991) Effect of selective
888 decontamination of the digestive tract on respiratory tract infections and mortality in
889 the intensive care unit. *Lancet* 338:859-862
- 890 134. Hurley JC (1995) Prophylaxis with enteral antibiotics in ventilated patients:
891 selective decontamination or selective cross-infection? *Antimicrob Agents Chemother*
892 39:941-947
- 893 135. Pileggi C, Bianco A, Flotta D, Nobile CG, Pavia M (2011) Prevention of ventilator-
894 associated pneumonia, mortality and all intensive care unit acquired infections by
895 topically applied antimicrobial or antiseptic agents: a meta-analysis of randomized
896 controlled trials in intensive care units. *Crit Care* 15:R155
- 897 136. Hurley JC (2008) Profound effect of study design factors on ventilator-associated
898 pneumonia incidence of prevention studies: benchmarking the literature experience. *J*
899 *Antimicrob Chemother* 61:1154-1161
- 900 137. Hurley JC (2011) Paradoxical Ventilator Associated Pneumonia incidences among
901 selective digestive decontamination studies versus other studies of mechanically
902 ventilated patients: benchmarking the evidence base. *Crit Care* 15:R7
- 903 138. Alexandersson, A (1998) gr32: Confidence ellipses. *Stata Technical Bulletin* 46:
904 10–13. In *Stata Technical Bulletin Reprints*, vol. 8, 54–57. College Station, TX: Stata
905 Press.

- 906 139. Alexandersson, A (2004) Graphing confidence ellipses: An update of ellip for Stata
907 8. *Stata Journal* 4:242-256
- 908 140. Friendly M, Monette G, Fox J (2013) Elliptical insights: understanding statistical
909 methods through elliptical geometry. *Statistical Science* 28: 1-39
- 910 141. Cleveland WS (1979) Robust locally weighted regression and smoothing
911 scatterplots. *Journal of the American Statistical Association* 74: 829-836
- 912 142. Stoutenbeek CP, van Saene HK, Miranda DR, Zandstra DF, Langrehr D (1987) The
913 effect of oropharyngeal decontamination using topical nonabsorbable antibiotics on the
914 incidence of nosocomial respiratory tract infections in multiple trauma patients. *J*
915 *Trauma* 27:357-364
- 916 143. Charles PE, Dalle F, Aube H, Doise JM, Quenot JP, Aho LS, Blettery B (2005)
917 *Candida* spp. colonization significance in critically ill medical patients: a prospective
918 study. *Intensive Care Med* 31:393-400
- 919 144. Rello J, Esandi ME, Diaz E, Mariscal D, Gallego M, Vallès J (1998) The role of
920 *Candida* sp isolated from bronchoscopic samples in nonneutropenic patients. *Chest*
921 114(1):146-149
- 922 145. Wood GC, Mueller EW, Croce MA, Boucher BA, Fabian TC (2006) *Candida* sp.
923 isolated from bronchoalveolar lavage: clinical significance in critically ill trauma
924 patients. *Intensive Care Med* 32(4), 599-603
- 925 146. Normand S, François B, Dardé ML, Bouteille B, Bonnivard M, Preux PM, Vignon,
926 P (2005) Oral nystatin prophylaxis of *Candida* spp. colonization in ventilated critically
927 ill patients. *Intensive Care Med* 31(11):1508-1513
- 928 147. El-Ebiary M, Torres A, Fabregas N, de la Bellacasa JP, Gonzalez J, Ramirez J,
929 Jiménez de Anta MT (1997) Significance of the isolation of *Candida* species from
930 respiratory samples in critically ill, non-neutropenic patients: an immediate postmortem
931 histologic study. *Am J Respir Crit Care Med* 156(2):583-590
- 932 148. Schnabel RM, Linssen CF, Guion N, van Mook WN, Bergmans DC (2014)
933 *Candida* pneumonia in intensive care unit? *Open forum infectious diseases* 1(1) p.
934 ofu026). Oxford University Press.
- 935 149. Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, Van
936 Wijngaerden E (2009) Significance of the isolation of *Candida* species from airway
937 samples in critically ill patients: a prospective, autopsy study. *Intensive Care Med*
938 35(9):1526-1531
- 939 150. Lau AF, Kabir M, Chen SCA, Playford EG, Marriott DJ, Jones M, Sorrell TC
940 (2015) *Candida* colonization as a risk marker for invasive candidiasis in mixed
941 medical-surgical intensive care units: Development and evaluation of a simple,
942 standard protocol. *J Clin Microbiol* 53:1324-1330
- 943 151. Delisle MS, Williamson DR, Perreault MM, Albert M, Jiang X, Heyland DK
944 (2008) The clinical significance of *Candida* colonization of respiratory tract secretions
945 in critically ill patients. *J Crit Care* 23(1):11-17
- 946 152. Williamson DR, Albert M, Perreault MM, Delisle M S, Muscedere J, Rotstein C,
947 Heyland DK (2011) The relationship between *Candida* species cultured from the
948 respiratory tract and systemic inflammation in critically ill patients with ventilator-
949 associated pneumonia. *Can J Anesthesia/Journal canadien d'anesthésie* 58(3):275-284

153. Albert M, Williamson D, Muscedere J, Lauzier F, Rotstein C, Kanji S, Heyland D (2014) Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). *Intensive Care Med* 40(9):1313-1322
154. Terraneo S, Ferrer M, Martín-Loeches I, Esperatti M, Di Pasquale M, Giunta V, Rinaudo M, de Rosa F, Li Bassi G, Centanni S, Torres A (2015) Impact of Candida spp. isolation in the respiratory tract in patients with intensive care unit-acquired pneumonia. *Clin Microbiol Infect* (in press)
155. Bailly S, Bouadma L, Azoulay E, Orgeas MG, Adrie C, Souweine B, Timsit JF (2015) Failure of Empirical Systemic Antifungal Therapy in Mechanically Ventilated Critically Ill Patients. *Am J Respir Crit Care Med* 191(10):1139-1146
156. Hamet M, Pavon A, Dalle F, Pechinot A, Prin S, Quenot JP, Charles PE (2012) Candida spp. airway colonization could promote antibiotic-resistant bacteria selection in patients with suspected ventilator-associated pneumonia. *Intensive Care Med* 38(8):1272-1279
157. de Smet AMGA, Kluytmans JAJW, Cooper BS, Mascini EM, Benus RFJ, van der Werf TS, van der Hoeven JG, Pickkers P, Bogaers-Hofman D, van der Meer NJ, Bernards AT, Kuijper EJ, Joore JC, Leverstein-van Hall MA, Bindels AJ, Jansz AR, Wesselink RM, de Jongh BM, Dennesen PJ, van Asselt GJ, te Velde LF, Frenay IH, Kaasjager K, Bosch FH, van Iterson M, Thijsen SF, Kluge GH, Pauw W, de Vries JW, Kaan JA, Arends JP, Aarts LP, Sturm PD, Harinck HI, Voss A, Uijtendaal EV, Blok HE, Thieme Groen ES, Pouw ME, Kalkman CJ, Bonten MJ (2009) Decontamination of the digestive tract and oropharynx in ICU patients. *N Engl J Med* 360:20–31
158. Hurley JC (2005) Inapparent outbreaks of ventilator-associated pneumonia: an ecologic analysis of prevention and cohort studies. *Infect Control Hosp Epidemiol* 26:374-390
159. Ong DS, Klouwenberg PMK, Spitoni C, Bonten MJ, Cremer O (2013) Nebulised amphotericin B to eradicate Candida colonisation from the respiratory tract in critically ill patients receiving selective digestive decontamination: a cohort study. *Crit Care* 17:R233
160. Van der Geest P J, Dieters EI, Rijnders B, Groeneveld JA (2014) Safety and efficacy of amphotericin-B deoxycholate inhalation in critically ill patients with respiratory Candida spp. colonization: a retrospective analysis. *BMC Infect Dis* 14:575
161. Ferreira D, Grenouillet F, Blasco G, Samain E, Hénon T, Dussaucy A, Pili-Floury S (2015) Outcomes associated with routine systemic antifungal therapy in critically ill patients with Candida colonization. *Intensive Care Med* 41:1077-1088
162. Mutapi F, Roddam A (2002) P values for pathogens: statistical inference from infectious-disease data. *Lancet Infect Dis* 2:219-230
163. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? (1983) interpreting zero numerators. *JAMA* 249:1743-1745

991

Table 1. Characteristics of studies ^a

	Observational studies	Groups of interventional studies of VAP prevention		
		Methods other than topical antibiotics	SDD	
			Non-concurrent	concurrent control
Study characteristics				
Sources [ref]	Table S1 [112-114]	Table S2 [115-120]	Table S3 [93-98]	Table S4 [93-98]
Number of studies	34	35	9	33
Origin from systematic review	6	17	4	29
EU origin ^b	19	23	7	31
MV for >48 hours for <75% ^c	4	1	2	2
Trauma ICUs ^d	4	5	3	8
Bronchoscopic sampling ^e	18	13	6	13
Group wide candidemia risk factors ^f	0	0	2	4
Study publication year (range)	1987-2014	1987-2014	1987-2014	1987-2007
Group characteristics				
Numbers of patients per study group; median (IQR) ^g	233 108-591	96 51-184	91 50-127	51 31-101
VAP incidence per 100 patients; (median; IQR; number of groups) ^g				
Cohort	20.4%; 14.1–31.0% (36)		NA	NA
Control	NA	20.6%; 14.8-26.5% (34)	45.5%; 23.0-59.3% (7)	30.4%; 18.5-48.1% (32)
Intervention	NA	13.2%; 9.0-21.7% (34)	10.1%; 7.6 – 16.7 (11)	11.8% 5.6-23.0% (35)

Table 1 (continued)

	Observational studies	Groups of interventional studies of VAP prevention		
		Methods other than topical antibiotics	SDD	
			Non-concurrent control	concurrent control
<hr/>				
Candidemia per 100 patients; mean; 95% CI (number of groups) ^h				
<hr/>				
Cohort	0.8%; 0.2–2.9% (6)			
Control		0.8%; 0.8-1.6% (5)	0.7%; 0.3-2.0% (5)	1.4%; 1.0- 1.8% (28)
Intervention		0.8%; 0.4-1.6% (8)	0.8%; 0.4-1.8% (10)	1.2%; 0.9-1.7% (29)
Overall <i>Candida</i> colonization per 100 patients; mean; 95% CI (number of groups) ⁱ				
<hr/>				
Cohort	9.7%; 3.0–27.0% (7)			
Control		4.8%; 1.1-18.6% (7)	9.8%; (1)	25.9%; ^j 12.8-45.5% (16)
Intervention		2.7%; 0.8-8.4% (7)	4.3%; 0.4-33.0% (4)	9.4%; ^j 4.3-19.1% (19)
Respiratory <i>Candida</i> per 100 patients mean; 95% CI (number of groups) ^k				
<hr/>				
Cohort	1.3%; 0.9–1.8% (36)			
Control		1.4%; 1.2-1.6% (33)	0.7%; 0.4-1.4% (6)	2.3%; 1.6-3.4% (32) ^l
Intervention		1.0%; 0.7-1.4% (33)	1.3%; 0.5- 3.0% (9)	1.4%; 1.0- 1.9% (35) ^l

Footnotes to table 1

- a. Abbreviations; ICU, Intensive care unit; MV; EU, European Union; Mechanical ventilation; NA not applicable; SDD , Selective Digestive Decontamination; VAP ventilator associated pneumonia; IQR, interquartile range
- b. Originating from a member state of the EU as at 2010 or Switzerland or Norway
- c. Studies for which less than 75% of patients were reported to receive more than 48 hours of mechanical ventilation.
- d. Trauma ICU defined as an ICU with >50% of patient admissions for trauma
- e. Bronchoscopic versus tracheal sampling toward the diagnosis of VAP
- f. One or more of the following risk factors were used for patient inclusion; use of TPN; major gastro-intestinal surgery or perforation; or liver transplantation
- g. Calculated including only groups for which >75% received >48 hours of MV
- h. See Fig. S7.
- i. *Candida* colonization not limited to patients with suspected VAP and not limited to respiratory sites. See Fig. S6
- j. Difference between intervention versus control groups from studies of SDD with concurrent design in a marginal analysis of the GEE model (as in Table S5) ; $p=0.001$
- k. *Candida* colonization limited to patients with suspected VAP and limited to lower respiratory sites.
- l. Difference between intervention versus control groups from studies of SDD with concurrent design in a marginal analysis of the GEE model (as in Table 2) ; $p=0.051$

Table 2: Logit RT *Candida* incidence; generalized estimating equation models (all groups) ^a

Factor	Coefficient ^b	95% CI	p
Groups from observational studies (reference group)	-4.31	-4.77 to -3.85	<0.001
Control groups			
• Non-TA ^c	+0.16	-0.32 to +0.64	0.51
• SDD/SOD; non-concurrent	+0.10	-0.86 to +1.06	0.84
• SDD/SOD; Concurrent ^d	+0.56	+0.08 to +1.04	0.021
Intervention groups			
• Non-TA	-0.02	-0.54 to +0.50	0.93
• SDD/SOD; non-concurrent	+0.26	-0.45 to +0.98	0.47
• SDD/SOD; Concurrent ^e	+0.12	-0.38 to +0.62	0.63
Candidemia risk factor	+1.40	+0.78 to +2.01	0.001
Trauma ^f	+0.007	+0.02 to +0.01	0.004
Year of publication ^g	-0.003	-0.02 to +0.02	0.82
EU origin	-0.06	-0.42 to +0.30	0.74
topical placebo use	+0.05	-0.31 to +0.40	0.80
Mode of diagnosis ^h	-0.19	-0.48 to +0.11	0.21

Footnotes

- This table displays the results of analysis using the Poisson model for the GEE model. The results obtained from a binomial model are similar (data not shown). Repeating the analysis excluding the three studies of SDD that did not include an anti-fungal within the SDD regimen failed to alter the findings here (data not shown).
- Interpretation. The reference group is the observational study (benchmark) groups and this coefficient equals the difference in logits from 0 (a logit equal to 0 equates to a proportion of 50%; a logit equal to -4.33 equates to a proportion of 1.3%) and the other coefficients represent the difference in logits for groups positive for that factor versus the reference group.
- Abbreviations; TA, topical antibiotic; SDD/SOD, selective digestive decontamination / selective oro-pharyngeal decontamination.
- Repeating the base model with the analysis limited to component groups from studies cited in systematic reviews results in this coefficient becoming +0.67; +0.08 to +1.27; p=0.026
- Repeating the base model with the analysis limited to component groups from studies cited in systematic reviews results in this coefficient becoming +0.01; -1.07 to +1.07; p=0.99

- f. The co-efficient for trauma represents the increment in logit for each percentage point increase in the proportion of admissions for trauma
- g. The co-efficient for year of publication represents the increment in logit for each year after 1985
- h. For sampling using bronchoscopic versus tracheal sampling

Figure legends.

Fig. 1 Search method, screening criteria and resulting classification of eligible studies and subsequent decant of component groups. The seven numbered arrows to the right represent steps in the process as discussed in the methods; steps one – five refer to studies and steps six- seven refer to component groups decanted from the studies being control (rectangles) and intervention (ovals) groups from ICU based studies of infection prevention methods and observation groups from cohorts of ICU patients without a prevention method under study (diamond). The horizontal dotted rectangles represent the group contrasts used toward the calculation of the contextual effects of the component groups each versus the observation groups as the reference category. Note; the total numbers do not tally as some systematic reviews provided studies in more than one category and some studies provided groups in more than one category. Note; SDD includes SOD and other methods based on the use of a topical antibiotic (TA)

Fig. 2 RT Candida incidence versus year of publication. Scatter plot of RT Candida incidence in observational groups (open black circles) versus year of study publication for which the linear regression was non-significant ($p = 0.72$) and hence a LOWESS regression line is given. Also shown are the control groups from studies of non-TA methods (open blue triangle) and also concurrent control (CC) studies of SDD/SOD (closed red triangles). Note that the symbols are proportional to group size and the y axis is a logit scale

Fig. 3 Scatter plots of RT Candida incidence. Scatter plots of RT Candida incidence in component (C = control; I = intervention) groups of non-TA and non-concurrent (NCC), and concurrent control (CC) studies of SDD (antibiotic methods) of VAP prevention (blue symbols). The benchmark RT Candida is the summary mean (central broken vertical line)

derived from the observation studies (black symbols) together with the 95% prediction intervals (benchmark range; outer broken vertical lines). Studies with MV for >48 hours for <75% and one outlier study [84] are not shown. Note that the x axis is a logit scale and that studies with a zero RT Candida can only be shown on this plot through use of the continuity correction. These data are displayed in more detail as caterpillar plots (Fig. S1-S4)

Fig. 4 Candidemia incidence versus RT Candida.

Fig. 4a Scatter plot of Candidemia incidence versus RT Candida incidence in observational groups and control groups from studies of non-TA methods (open black circles) for which both data were available. Both a linear regression ($p=0.057$) and a 95% prediction ellipse based on these groups are shown. Also shown are the intervention groups from studies of non-TA methods (closed triangles). Also shown are the mean (central) and 95% prediction lines (outer) derived for the full set of benchmark groups for both RT candida (vertical) and candidemia (horizontal). Note that both the x and the y axes are a logit scale

Fig. 4b Scatter plot of Candidemia incidence versus RT Candida incidence in control (closed green triangles) and intervention (open green triangles) groups from studies of non-concurrent design studies of SDD (open green triangles) for which both data were available. The linear regression, 95% prediction ellipse and mean and 95% prediction lines from Fig. 4a are shown for reference

Fig. 4c Scatter plot of Candidemia incidence versus RT Candida incidence in control (closed green triangles) and intervention (open red triangles) groups from studies of concurrent design studies of SDD (open red triangles) for which both data were available.

The linear regression, 95% prediction ellipse and mean and 95% prediction lines from Fig. 4a are shown for reference. Note that one outlier study [84] is not shown

Figure 2

Figure 3

Figure 4a

Figure 4b

Figure 4c